Jessica Glennie, MSN, APRN

Jessica Glennie, MSN, APRN, says the first formal ATS clinical guidelines on interstitial lung abnormalities are filling a real gap — but integration into practice is still catching up.

With nerandomilast offering a more tolerable alternative to nintedanib and pirfenidone, Jessica Glennie, MSN, APRN, says the threshold for initiating antifibrotic therapy in early or stable disease is moving up.

The CNP at Cleveland Clinic discusses how early recognition, cross-specialty collaboration, and extended patient engagement make APPs essential in the complex, long-term care of interstitial lung disease.